FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912345299> ?p ?o ?g. }

• W2912345299 abstract "Article Abstract Objective: To report the symptomatic and functional outcomes in patients with major depressive disorder (MDD) during a 2-phase treatment trial and to estimate the value of early improvement after 2 weeks in predicting clinical response to escitalopram and subsequently to adjunctive treatment with aripiprazole. Methods: Participants with MDD (N = 211) identified with the Montgomery-Asberg Depression Rating Scale (MADRS) and confirmed with the Mini-International Neuropsychiatric Interview were recruited from 6 outpatient centers across Canada (August 2013 through December 2016) and treated with open-label escitalopram (10-20 mg) for 8 weeks (Phase 1). Clinical and functional outcomes were evaluated using the MADRS, Quick Inventory of Depressive Symptomatology-Self-Rated (QIDS-SR), Sheehan Disability Scale (SDS), and Lam Employment Absence and Productivity Scale (LEAPS). Participants were evaluated at 8 and 16 weeks for clinical and functional response and remission. Phase 1 responders continued escitalopram while nonresponders received adjunctive aripiprazole (2-10 mg) for a further 8 weeks (Phase 2). Results: After Phase 1, MADRS response (≥ 50% decrease from baseline) and remission (score ≤ 10) were, respectively, 47% and 31%, and SDS response (score ≤ 12) and remission (score ≤ 6) were, respectively, 53% and 24%. Response to escitalopram was maintained in 91% of participants at week 16, while 61% of the adjunctive aripiprazole group achieved MADRS response during Phase 2. Response and remission rates with the QIDS-SR were lower than with the MADRS. The LEAPS demonstrated significant occupational improvement (P < .05). Early symptomatic improvement predicted outcomes with modest accuracy. Conclusions: This study demonstrates comparable symptomatic and functional outcomes to those of other large practical-design studies. There was a high response rate with the adjunctive use of aripiprazole in escitalopram nonresponders. Given the limited value of early clinical improvement to predict outcome, integration of clinical and biological markers deserves further exploration. Trial Registration: ClinicalTrials.gov identifier: NCT01655706" @default.
• W2912345299 created "2019-02-21" @default.
• W2912345299 creator A5002538047 @default.
• W2912345299 creator A5006781690 @default.
• W2912345299 creator A5009298184 @default.
• W2912345299 creator A5013738913 @default.
• W2912345299 creator A5015434278 @default.
• W2912345299 creator A5015821361 @default.
• W2912345299 creator A5017050709 @default.
• W2912345299 creator A5020523131 @default.
• W2912345299 creator A5022065571 @default.
• W2912345299 creator A5022694312 @default.
• W2912345299 creator A5023923022 @default.
• W2912345299 creator A5024738405 @default.
• W2912345299 creator A5026791700 @default.
• W2912345299 creator A5028689323 @default.
• W2912345299 creator A5032968625 @default.
• W2912345299 creator A5033098260 @default.
• W2912345299 creator A5036308969 @default.
• W2912345299 creator A5038002116 @default.
• W2912345299 creator A5039458476 @default.
• W2912345299 creator A5040971877 @default.
• W2912345299 creator A5045133349 @default.
• W2912345299 creator A5049270203 @default.
• W2912345299 creator A5051165798 @default.
• W2912345299 creator A5051880625 @default.
• W2912345299 creator A5058161363 @default.
• W2912345299 creator A5058529837 @default.
• W2912345299 creator A5063025917 @default.
• W2912345299 creator A5063778915 @default.
• W2912345299 creator A5067529083 @default.
• W2912345299 creator A5075071973 @default.
• W2912345299 creator A5090658899 @default.
• W2912345299 creator A5090699665 @default.
• W2912345299 date "2019-02-05" @default.
• W2912345299 modified "2023-10-10" @default.
• W2912345299 title "Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder" @default.
• W2912345299 doi "https://doi.org/10.4088/jcp.18m12202" @default.
• W2912345299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30840787" @default.
• W2912345299 hasPublicationYear "2019" @default.
• W2912345299 type Work @default.
• W2912345299 sameAs 2912345299 @default.
• W2912345299 citedByCount "54" @default.
• W2912345299 countsByYear W29123452992019 @default.
• W2912345299 countsByYear W29123452992020 @default.
• W2912345299 countsByYear W29123452992021 @default.
• W2912345299 countsByYear W29123452992022 @default.
• W2912345299 countsByYear W29123452992023 @default.
• W2912345299 crossrefType "journal-article" @default.
• W2912345299 hasAuthorship W2912345299A5002538047 @default.
• W2912345299 hasAuthorship W2912345299A5006781690 @default.
• W2912345299 hasAuthorship W2912345299A5009298184 @default.
• W2912345299 hasAuthorship W2912345299A5013738913 @default.
• W2912345299 hasAuthorship W2912345299A5015434278 @default.
• W2912345299 hasAuthorship W2912345299A5015821361 @default.
• W2912345299 hasAuthorship W2912345299A5017050709 @default.
• W2912345299 hasAuthorship W2912345299A5020523131 @default.
• W2912345299 hasAuthorship W2912345299A5022065571 @default.
• W2912345299 hasAuthorship W2912345299A5022694312 @default.
• W2912345299 hasAuthorship W2912345299A5023923022 @default.
• W2912345299 hasAuthorship W2912345299A5024738405 @default.
• W2912345299 hasAuthorship W2912345299A5026791700 @default.
• W2912345299 hasAuthorship W2912345299A5028689323 @default.
• W2912345299 hasAuthorship W2912345299A5032968625 @default.
• W2912345299 hasAuthorship W2912345299A5033098260 @default.
• W2912345299 hasAuthorship W2912345299A5036308969 @default.
• W2912345299 hasAuthorship W2912345299A5038002116 @default.
• W2912345299 hasAuthorship W2912345299A5039458476 @default.
• W2912345299 hasAuthorship W2912345299A5040971877 @default.
• W2912345299 hasAuthorship W2912345299A5045133349 @default.
• W2912345299 hasAuthorship W2912345299A5049270203 @default.
• W2912345299 hasAuthorship W2912345299A5051165798 @default.
• W2912345299 hasAuthorship W2912345299A5051880625 @default.
• W2912345299 hasAuthorship W2912345299A5058161363 @default.
• W2912345299 hasAuthorship W2912345299A5058529837 @default.
• W2912345299 hasAuthorship W2912345299A5063025917 @default.
• W2912345299 hasAuthorship W2912345299A5063778915 @default.
• W2912345299 hasAuthorship W2912345299A5067529083 @default.
• W2912345299 hasAuthorship W2912345299A5075071973 @default.
• W2912345299 hasAuthorship W2912345299A5090658899 @default.
• W2912345299 hasAuthorship W2912345299A5090699665 @default.
• W2912345299 hasConcept C118552586 @default.
• W2912345299 hasConcept C126322002 @default.
• W2912345299 hasConcept C138496976 @default.
• W2912345299 hasConcept C139719470 @default.
• W2912345299 hasConcept C15744967 @default.
• W2912345299 hasConcept C162324750 @default.
• W2912345299 hasConcept C2776412080 @default.
• W2912345299 hasConcept C2776466505 @default.
• W2912345299 hasConcept C2776867660 @default.
• W2912345299 hasConcept C2779144063 @default.
• W2912345299 hasConcept C2779177272 @default.
• W2912345299 hasConcept C2779583969 @default.
• W2912345299 hasConcept C2780051608 @default.
• W2912345299 hasConcept C2780211496 @default.
• W2912345299 hasConcept C2781161787 @default.
• W2912345299 hasConcept C71924100 @default.
• W2912345299 hasConcept C83849319 @default.
• W2912345299 hasConceptScore W2912345299C118552586 @default.
• W2912345299 hasConceptScore W2912345299C126322002 @default.

• next